The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for physicians and other qualified healthcare providers to apply.
These are temporary codes assigned to emerging technologies, services and procedures, to facilitate reimbursement and support access to psychedelic therapies in the U.S.
The data collected through the use of the new CPT III codes could reflect sufficient usage, and eventually lead to them being converted to permanent CPT I codes, with a valuation assigned for widespread coverage and reimbursement.
First announced in July 2023, the codes have been jointly championed by the for-profit arm of the legendary Multidisciplinary ...